SUZHOU, China, October 14, 2020 (PRLOG) – Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell therapies targeting osteoarthritis, spinal cord injury and various cancers was recently presented a 2020 “China’s Most Promising Company” award by Ernst & Young and the School of Management of Fudan University.
This was the tenth annual “Ernst & Young Fudan China’s Most Promising Company” competition. The selection committee nominates early-stage, fast-growth companies who they see with the potential to become industry leaders for China’s strategic industries, including healthcare, biotechnology, and aerospace. To date, 200 companies have received this accolade, among which 39 have successfully listed publicly.
“We are grateful that Ernst & Young and Fudan University have identified Re-Stem Biotech for our achievements in innovative biotechnology,” commented Judyanna Yu, Chief Operations Officer and Chief Financial Officer of Re-Stem. “In the spirit of this award, becoming an industry leader with the mission to effect positive change, Re-Stem will continue to develop products and therapies targeting unmet medical needs in China, and to help improve manufacturing processes and treatment outcomes internationally.”
About Re-Stem Biotech
Re-Stem Biotech (Re-Stem) is a biotechnology firm engaged in the research and development of cell-based therapies and products. Backed by state of the art GMP facilities and an international team of world-leading scientists, doctors and management team, Re-Stem currently has a robust technology platform including four profitable therapies on the market and eight other therapies and products in the pipeline. Incorporated and headquartered in 2012 in Suzhou, China, Re-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing, Kunming and Ganzhou. For more information visit Re-Stem Biotech website: https://www.restembio.com/
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as “will,” “may,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although Re-Stem believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, performance or achievements will be obtained. Re-Stem does not have any obligation to update these forward-looking statements other than as required by law.
Contact:
Judyanna Yu
COO & CFO
Re-Stem Biotech